Do Negative Trials Count More Than Successful Ones?
This article was originally published in The Pink Sheet Daily
Fabre-Kramer, FDA dispute over efficacy of the antidepressant gepirone heads to Psychopharmacologic Drugs Advisory Committee.
You may also be interested in...
Will Alkermes Data Package Support ALKS 5461 Approval?
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
FDA Ruling On Gepirone Efficacy Data Delayed By One Month
Fabre-Kramer responds to Office of New Drugs Director Jenkins' invitation to submit additional information following advisory committee review; Jenkins' decision on the antidepressant now expected by end of January.
Defining 'Substantial Efficacy': Post Hoc Analysis OK (When FDA Does It)
Agency's interpretation of four unsuccessful trials of Fabre-Kramer's antidepressant seems like 'cherry picking' and could create an uneven playing field for sponsors, some advisory committee members say; nevertheless, panel overwhelmingly concludes efficacy was lacking.